Navigation Links
HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences
Date:7/14/2008

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- HealthSonix, Inc. (Pink Sheets: HSXI)(FWB:H7S) today announced that Innovative Health Sciences, Inc. (Pink Sheets: IHSI) has purchased two wholly owned subsidiaries of HealthSonix, Inc. in exchange for 35,356,000 IHSI common shares.

"Selling the two operating companies to Innovative Health Sciences (http://www.InnovativeHS.com) will immediately allow the companies to resume full operations and get back to implementing their business plan," said Dieter Doederlein, Vice President Corporate Development for HealthSonix. "As part of the agreement, Innovative Health Sciences has committed to injecting significant working capital into the operations to expedite the delivery of the Gen II hand held enSonix medical devices and to allow us to expand the distribution of the ZingiberRx Joint and Muscle cream," added Doederlein.

All HealthSonix shareholders of record as of July 14, 2008 will receive IHSI shares on a pro rata basis in exchange for their HSXI shares. The anticipated exchange ratio is .6 IHSI shares for every 1.00 HSXI share. The shares will be distributed to our shareholders in due course.

"Effectively, the current HealthSonix shareholders, as a group, become the majority shareholders in IHSI," said Chris Winter, CEO of Innovative Health Sciences. "Our management and our shareholders are extremely pleased with this acquisition, and we look forward to making our contribution to the immense growth potential and anticipated success of the HealthSonix products."

Following the completion of the transaction, HealthSonix, Inc. will change its name to HSX Holdings, Inc.

HSX Holdings, Inc. (formerly HealthSonix, Inc. - HSXI) is a holding company with ownership interest in Innovative Health Sciences, Inc. [IHSI]. All current HSXI shareholders have indirect ownership in IHSI. For more information, please visit http://www.hsxholdings.com.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.


'/>"/>
SOURCE HealthSonix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Sells Quebec City Building for $7.1 million
2. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
6. Exelixis Sells 80% Stake in Artemis to Taconic
7. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. IBT Laboratories Names Maureen Loftus President and Chief Operating Officer
10. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
11. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):